ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Effects of high- versus low-intensity lipid-lowering treatment in patients undergoing serial coronary computed tomography angiography: results of the multi-center LOCATE study.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- In search of the vulnerable plaque: Chasing waterfalls or precision medicine?The international journal of cardiovascular imaging · 2026Article
- Cardiac computed tomography unmasks cardiac involvement in immune complex vasculitis in a patient with chest pain and shortness of breath.European heart journal. Case reports · 2026Article
- Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- [Cardiovascular imaging using cardiac computed tomography and cardiac magnetic resonance imaging].Herz · 2026Review
- Observer variabilities for the diagnosis of coronary artery disease using anatomical and functional testing: the impact of certification.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Emerging quantitative CCTA imaging biomarkers for cardiovascular risk stratification: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review.Current atherosclerosis reports · 2025Review
- Longitudinal Effects of Lipid-Lowering Treatment on High-Risk Plaque Features and Pericoronary Adipose Tissue Attenuation Using Serial Coronary Computed Tomography.Diagnostics (Basel, Switzerland) · 2025Article
- Machine learning paving the way for successful antegrade crossing of total chronic coronary occlusions.Cardiovascular diagnosis and therapy · 2024Article
- Diagnostic utility of coronary artery calcium score percentiles and categories to exclude abnormal scans and relevant ischemia in rubidium positron emission tomography.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the effects of lipid-lowering medications of different intensities on total, calcified, and non-calcified plaque volumes in patients undergoing serial cardiac computed tomography angiography (CCTA).
methodsIndividuals with chronic coronary syndromes from 11 centers were included in a retrospective registry. Total, calcified, and non-calcified plaque volumes were quantified and the relative difference in plaque volumes between baseline and follow-up CCTA was calculated. The intensity of lipid-lowering treatment was designated as low, moderate, or high, based on current recommendations.
resultsOf 216 patients (mean age 63.1 ± 9.7 years), undergoing serial CCTA (median timespan = 824.5 [IQR = 463.0-1323.0] days), 89 (41.2%) received no or low-intensity lipid-lowering medications, and 80 (37.0%) and 47 (21.8%) moderate- and high-intensity lipid-lowering agents, respectively. Progression of total and non-calcified plaque was attenuated in patients on moderate-/high- versus those on no/low-intensity treatment and arrested in patients treated with high-intensity statins or PCSK9 inhibitors (p < 0.001). Halted increase of non-calcified plaque was associated with LDL-cholesterol reduction (p < 0.001), whereas calcified plaque mass and Agatston score increased irrespective of the lipid-lowering treatment (p = NS). The intensity of lipid-lowering therapy robustly predicted attenuation of non-calcified plaque progression as a function of the time duration between the two CCTA scans, and this was independent of age and cardiovascular risk factors (HR = 3.83, 95% CI = 1.81-8.05, p < 0.001).
conclusionThe LOCATE multi-center observational study shows that progression of non-calcified plaques, which have been previously described as precursors of acute coronary syndromes, can be attenuated with moderate-intensity, and arrested with high-intensity lipid-lowering therapy. GERMAN CLINICAL TRIALS REGISTER: DRKS00031954.
Indexed as
Identifiers
39080016What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.